Theme: Neuropharmacology: Major Challenges and Breakthroughs

Neuropharmacology 2017

Neuropharmacology 2017

Conference Series LLC Conferences invites all the participants from all over the world to attend "7th Global Experts Meeting on Neuropharmacology" during July 31-Aug 02, 2017 at Milan, Italy which includes prompt Keynote Presentations, Oral talks, Poster presentations and Exhibitions.

Neuropharmacology 2017 is the learning of how drugs influence cellular function in the nervous system, and the neural mechanisms through which they influence behavior. The studies are more concerned with the interactions of neurotransmitters, neuropeptides, neurohormones, neuromodulators, enzymes, second messengers, co-transporters, ion channels, and receptor proteins in the central and peripheral nervous systems. Advanced studies are being made to improvise developments in drugs to treat numerous diverse neurological disorders, including neurodegenerative diseases known to be Parkinson's disease and Alzheimer's disease, pain, addiction, psychological disorders and many more. Conference Series LLC organizes a conference series of 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.

Track 1: Neuroimmunology and Neuroinflammation

It deals with a branch of immunology concerned with the interactions between immunological and nervous system functions also associated autoimmune diseases.  Cortical system involves the study of mapping neural systems associated in the processing of emotion, and it focuses on the cortical components of the process of recognizing facial expressions. Encephalitis is acute inflammation of the brain resulting from a viral infection or an autoimmune disease. Transverse myelitis is a pathogenetically heterogeneous inflammatory disorder in which spinal cord is affected. Huntington disease is a progressive brain disorder that causes uncontrolled movements, emotional problems, and loss of thinking ability.

Blood brain barrier is a selectively permeable membrane that separates the blood in the brain from other extracellular fluids. Meningitis, epilepsy, cerebral edema, multiple sclerosis etc. are various diseases associated with it. The children of age group 1 to 14 are more prone to cancer, out of which 18% is the case of brain tumour. In the first three decades of life, central nervous system has emerged as one of the three vulnerable leading sites for cancer mortality. Cerebral lymphoma is the most rapidly increasing brain tumour. 

Track 2: Neural Stem Cell

Neural stem cells (NSCs) offer a unique and powerful tool for basic research and regenerative medicine. To date the need to accomplish this has just been met to some degree for neurons got from embryonic undeveloped cells or iPS cells, and still, after all that the information is not of a quality to justify clinical trials. The issue is that, while the cells that can be made in the lab resemble the ones required, they frequently do not have certain fundamental attributes. 

Track 3: Neuroethics

It includes the social, legal and ethical consequences of advances in neuroscience. It is the amalgamation of neuroscience with ethical thoughts. The ethics of neurocognitive includes brain interventions and imagining, neurological treatments and consciousness disorders. 

Track 4: Clinical Neuropharmacology

It is the science that studies the features, properties, responses and uses of drugs mainly their therapeutic effect in humans along with toxicology, pharmacodynamics and pharmacokinetics. It also includes drug abuse, pain and hypothalamic releasing factors. 

Track 5: Psychopharmacology

Psychopharmacology is the learning of the effects of medication on the psyche (psychology), observing changed behaviors and how molecular events are manifest in a measurable behavioral form. Neurogenesis and repair deal with other aspects on the indications for medications prescribed to address psychiatric and behavioral problems, that are associated with, including antipsychotic, anxiolytic and anticonvulsant medications, acquired brain injury and psychopharmacology drugs and their interaction with neurotransmitters also include mood stabilizers and treatments prescribed for disorders of attention. The treatments may cause side effects such as induction of the metabolic syndrome, type II diabetes related to the medications prescribed for management of psychiatric and behavioural disorders and disturbances. The effectiveness of the drugs can be increased by prescriber’s knowledge over emotional and interpersonal issues of the patient i.e. psychology of psychopharmacology. Schizophrenia is such a disorder which affects the thinking and acting ability of a person caused by viral infection, genetically or by immune disorder.   

Track 6: Neurochemical Transmission

Neurochemistry is the specific study of neurochemicals, including neurotransmitters and other molecules that include psychopharmaceuticals, neuropeptides, or gastrotransmitters that influence the function of neurons. It also deals how these neurochemicals influence the network of neural operation. The studies include micro-macro connection between the analysis of organic compounds active in the nervous system and neural processes such as cortical plasticity, neurogenesis and neural differentiation, synapses, autism and intellectual disability, interneuronal coordination, interaction of drugs and its effect on summation and cotransmission process and advances in astrocyte-neuron interactions in health. Astrocyte dysfunction results into neurodegenerative diseases, stroke, epilepsy, migraine and neuroinflammatory diseases.

Track 7: Behavioral and Addiction Neuropharmacology

It is the study of drug dependence and how drug addiction affects the human mind, Anxiety and Autism, Measuring neural activity in Drug abuse, Alcoholism- tolerance to and physical dependence, and properties are mediated through its effects on dopamine neurons in the mesolimbic reward pathway, which connects the ventral tegmental area to the nucleus accumbens, Post-traumatic stress disorder and borderline personality disorder, clinical depression and enhanced treatments.

Track 8: Neurotechnology and its Advances

It is the measurement and analysis of chemical and electrical signals of nervous system. It includes neurocircuitary analysis, novel trans-synaptic tracing approaches, advancements of optical techniques, neuromodulation and transcranial magnetic stimulation. Neurotechnology plays a crucial role in diagnostics and identification of nervous activities.

Track 9: Neuroendocrinology

It is the study of interactions between the nervous system and the endocrine system, also biological features of the cells involved and their communications. Most Important aspects of neuroendocrinology are insulin receptor and hypothalamic programming; stress, coping and interactions, neuro-endocrine-immune symphony, pituitary structure and hormone secretion.

Track 10: Alzheimer's Disease and Dementia

Alzheimer's is a type of dementia that causes problems with memory, thinking and behaviour. Symptoms usually develop slowly and become severe enough to interfere with daily tasks. Amyloid plaques are also found in the brain of Alzheimer patients. Neurocognitive effects associated with therapeutic drugs and animal cognition and behaviour - Fear and aversive learning and memory.

Track 11: Parkinson’s Disease

It is a progressive and chronic disorder, caused by death or malfunctioning of neurons, genetic mutation leading to decreased level of dopamine secretion. Associated effects are anxietydepression, stress, ageing and neurodegenerative disorders, disease diagnostics, drug designing and therapeutics are the research areas.

Track 12: Molecular Neuropharmacology

Molecular neuropharmacology involves the study of neurons and agonist, Competitive antagonist and Non-competitive antagonist, receptors on neurons for developing new drugs that will treat neurological disorders of neurodegenerative diseases. Neurogenesis and repair refers to the growth and development of neuron. Neurons never function in isolation; they are organized into ensembles or circuits that process kinds of information which are referred as neuronal circuits. The GABA inhibitory neurotransmitter and serotonin neurotransmitter present in the central nervous system of mature vertebrate interacts with GABA receptor and 5HT receptor respectively. GABAA receptors are modulated by the channel of 5HT receptors through activation of various proteins. There are about 14 5HT receptor subtypes identified from last 20 years which are now researched for their significance in various disorders and treatments. Synaptopathy is a progressively popular term used to define main features of psychiatric and neurodegenerative diseases. It infers that brain diseases are resulted from disruption of synaptic structure and function.

Track 13: Future Aspects of Neuropharmacology

Neuropharmacology is an emerging field of science, rising exponentially with the understanding of nervous system and its related disorders, drugs and treatments. The major area of research includes mechanisms of novel drugs, neuro stem cell therapy, immunoglobulin therapy, gene therapy in neuronal disorders and neural engineering. 

Track 14: Case Study Reports

Case studies are an extremely useful records of the clinical practices of a profession. They are a record of clinical interactions which help us to frame questions for more rigorously designed clinical studies. Case studies also provide valuable teaching material, demonstrating both classical and unusual presentations which may challenge the practitioner.

Track 15: Entrepreneurs Investment Meet

A platform aimed to connect Entrepreneurs, Proposers and the Investors worldwide. It's intended to create and facilitate the most optimized and viable meeting place for engaging people in global business discussions, evaluation and execution of promising business ideas. An investor could be able to find out the highest potential investment opportunities globally, which provide good return on investment. For entrepreneurs, this would be an ideal place to find out suitable investors and partners to start and/or expand their business. Thus it is a perfect place to connect Entrepreneurs, Business Owners, Early Stage Companies and Established Corporates with National or International Investors, Corporate Investors and Potential Business Partners.

Conference Series LLC is a renowned organization that organizes highly notable  conferences throughout the globe. Currently we are bringing forth "7th Global Experts Meeting on Neuropharmacology” (Neuropharmacology 2017) scheduled to be held during July 31-Aug 02, 2017 at Milan, Italy. The conference invites all the participants across the globe to attend and share their insights and convey recent developments in the field of PharmBiotech and Clinical Trials.

Conference Series LLC organizes a conference series of 1000+ Global Events inclusive of 1000+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

2017 Highlights:

  • 300+ Participation (70 Industry: 30 Academia)
  • 5+ Keynote Speakers
  • 50+ Plenary Speakers
  • 20+ Exhibitors
  • 14 Innovative Educational Sessions
  • 5+ Workshops
  • B2B Meetings

Summary: Neuropharmacology 2017 welcomes attendees, presenters, and exhibitors from all over the world to San Antonio, USA. We are delighted to invite you all to attend and register for the “7th Global Experts Meeting on Neuropharmacology (Neuropharmacology 2017)” which is going to be held during July 31-Aug 02, 2017 at Milan, Italy. The organizing committee is gearing up for an exciting and informative conference program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We invite you to join us at the Neuropharmacology-2017, where you will be sure to have a meaningful experience with scholars from around the world. All the members of Neuropharmacology 2017 organizing committee look forward to meet you at San Antonio, USA.

For more details please visit-

Importance and Scope:  Neuropharmacology is the study of how drugs influence cellular function in the nervous system, and the neural mechanisms through which they influence behaviour. The studies are more concerned with the interactions of neurotransmitters, neuropeptides, neurohormones, neuromodulators, enzymes, second messengers, co-transporters, ion channels, and receptor proteins in the central and peripheral nervous systems. Advanced studies are being made to improvise developments in drugs to treat numerous diverse neurological disorders, including neurodegenerative diseases known to be Parkinson's disease and Alzheimer's disease, pain, addiction, psychological disorders and many more.

It is necessary to focus on neuropharmacology and the use of neuropharmaceuticals to transform brain processes in the way of enhancing memory, mood, sensation, thinking and attention in people.

Comparative analysis for Neurological Disorders (Age wise profile)

Conference Highlights

  • Neuroimmunology and Neuroinflammation
  • Neural Stem Cell
  • Molecular Neuropharmacology
  • Clinical Neuropharmacology
  • Psychopharmacology
  • Neurochemical Transmission
  • Behavioral and Addiction Neuropharmacology
  • Neurotechnology
  • Neuroendocrinology
  • Alzheimer’s Disease and Dementia
  • Parkinson’s Disease
  • Neuroethics
  • Future Aspects of Neuropharmacology
  • Case Study Reports

Attendance Profile according to specialization in a Neuroscience Conference

Hospitals of Neuropharmacology

Top Hospitals 

  • Mayo Clinic, Rochester, Minnesota
  • Johns Hopkins Hospital, Baltimore, Maryland
  • Massachusetts General Hospital, Boston
  • University of California–San Francisco Medical Center
  • Mathodist Hospital, San Antonio
  • University of California–Los Angeles Medical Center
  • New York University Langone Medical Center, New York City
  • Hospitals of the University of Pennsylvania–Penn Presbyterian
  • Northwestern Memorial Hospital, Chicago
  • Baptist Medical Centre, San Antonio


Major Neuropharmacology related Associations around the Globe

  • Canadian Neurological Sciences Federation
  • European Parkinson’s disease Association
  • Malaysian Society of Neurosciences
  • Eurospine, The Spine Society Of Europe
  • The Spanish Society of Neurology (SEN)
  • The Czech Neuropsychopharmacological Society
  • Belgian Neurological Society
  • National Neurotrauma Society 
  • National Parkinson'S Foundation
  • European Society Of Neurosonology And Cerebral Hemodynamics
  • Federation Of European Neuroscience Societies
  • Malaysian Society Of Neurosciences
  • Česká Neurologická Společnost
  • The Czech Neuropsychopharmacological Society
  • European Academy Of Neurology
  • Deutsche Gesellschaft Fur Neurologieologie 
  • International Brain Research Organization
  • The Neuropathy Association
  • The Primary Care Neurology Society
  • The Spanish Society Of Neurology (SEN)

Major Neuropharmacology related Associations in USA

  • International Neuroethics Society
  • Society for Behavioral Neuroendocrinology
  •  Society For Neuroscience
  • American Psychological Association
  • International Parkinson and Movement Disorder Society
  • American Neurological Association
  • National Institute Of Environmental Health Sciences
  • The American Society of Neuroimaging
  • American Board Of Psychiatry And Neurology, Inc.
  • American Clinical Neurophysiology Society
  • International Neuropsychological Society
  • Southern Clinical Neurological Society
  • International Parkinson And Movement Disorder Society

Universities in USA

  • Stanford University
  • University of North Carolina—​Chapel Hill
  • University of Minnesota
  • University of Kentucky
  • University of Washington
  • University of Texas
  • University of California
  • University of Maryland
  • Trinity University
  • Texas Southern University
  • University of Houston

Products for Neurological Treatments

This above statistic displays the global revenue of Abilify from Bristol-Myers Squibb from 2011 to 2014. In the United States alone, Abilify generated a revenue of 2.1 million U.S. dollars in 2012. Abilify is an antipsychotic agent that is used to treat various conditions such as schizophrenia, bipolar mania disorder, and major depressive disorder.

Gross Profit Margin of Neuropharmaceutical related companies

Market Capitalization of Neuropharmaceutical companies: In 2014, investors provided $3.3 billion into firms that are developing drugs for brain-destroying or psychiatric illnesses. Some big drug companies, including Johnson & Johnson, Roche and Novartis, are finding ways to reinvigorate their efforts. New medicines for severe depression, psychosis and schizophrenia could reach the market within the next few years, and treatments for Alzheimer’s, Parkinson’s and some forms of autism are a real possibility, too.

Sales Profile of Neuropharmaceutical companies

Research Fund: NIH (National Institute of Health) and NSFC (Nature Science Foundation of China) provided fund for the neurological disorders such as dementia, schizophrenia, stroke, parkinson’s, epilepsy.

Institutes funding for research

1)      The US National Institutes of Health fund a Neuropharmacology Laboratory project, Universitat Pompeu Fabra, Barcelona

2)      Neuropharmacology Program, The National Institute of Mental Health (NIMH)

3)      McKnight Endowment Fund for Neuroscience

  • The statistic depicts the research and development expenditure of the entire pharmaceutical industry of the United States from 1995 to 2014. In 2004, the expenditure of the entire U.S. pharmaceutical industry on research and development came to 47.6 billion U.S. dollars.
Neuropharmacology 2016

We gratefully thank all our wonderful Speakers, Conference Attendees, Students, Media Partners, Associations and Exhibitors for making Neuropharmacology 2016 Conference the best ever!

The 4th Global Experts Meeting on Neuropharmacology, hosted by the Conference Series LLC was held during September 14-16, 2016 at Hilton San Antonio Airport, San Antonio, USA based on the theme Innovations and Complications in Neuropharmacological Studies". Benevolent response and active participation was received from the Organizing Committee Members along with Scientists, Researchers, Students and leaders from various fields of Neuropharmacology, who made this event a grand success.

Conference Series LLC expresses its gratitude to the conference Moderator, namely Dr. Reginald Lafleur and Phenix Alcide from Harlem Cardiology, USA for taking up the responsibility to coordinate during the sessions. We are indebted to your support.

The conference was initiated with the Honourable presence of the Keynote forum. The list includes:

We are grateful to our Symposium and workshop organizers. The list comprises:

The meeting reflected various sessions, in which discussions were held on the following major scientific tracks:

  • Neuro Immune Pharmacology
  • Molecular Neuropharmacology
  • Psychopharmacology
  • Neurochemical Transmission
  • Behavioral Neuropharmacology
  • Neurotechnology
  • Neuroendocrinology
  • Alzheimer’s Disease and Dementia
  • Parkinson’s Disease
  • Neuroethics
  • Future Aspects of Neuropharmacology
  • Clinical Neuropharmacology
  • Chemical Neurotransmitters
  • Case Study Reports
  • Entrepreneurs Investment Meet

Conference Series LLC offers its heartfelt appreciation to organizations such as Bulgarian Society of NeurologyHuman Behavior Laboratory and our esteemed supporters KOWA,Federation of all European Neuroscience Societies (FENS), MedtubeSchizophrenia International Research SocietySelectScience and other eminent personalities who supported the conference by promoting in various modes online and offline which helped the conference reach every nook and corner of the globe. Conference Series LLC also took privilege to felicitate the Keynote Speakers, Organizing Committee Members, Chairs and Exhibitors who supported this event.

With the grand success of Neuropharmacology 2016Conference Series LLC is proud to announce the "7th Global Experts Meeting on Neuropharmacology" to be held during July 31-Aug 02, 2017 at Rome, Italy

Past Reports  Gallery  

Pharmacology 2016

Past Reports  Gallery  

Click here to submit abstract to any of the above topics


Want to Differentiate your company from your competitors and broaden your competitive edge?

Use our global platform of 3000+ Global Events

  • 25 Million+ Visitors to our Global website (
  • 20000+ Unique Visitors per conference
  • 60000+ Page views per conference

For customized sponsorship opportunities at our conferences, or to place an ad on our websites, contact at or call at: +1-650-268-9744

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date July 31-Aug 02, 2017
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity Day 1 Day 2 Day 3
Poster Opportunity Available

Conferenceseries Destinations